Spots Global Cancer Trial Database for Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
Official Title: A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma
Study ID: NCT01752205
Conditions
Study Description
Brief Summary: The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
307 Hospital of PLA, Beijing, Beijing, China
Contact Details
Name: Xu jianming, M.D.
Affiliation: The Affiliated Hospital of the Chinese Academy of Military Medical Science
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
